Maximus review
Compounded preparations and the manufacturers' pens are listed side by side on this seller's plans.
The verdict
Maximus prices compounded semaglutide at $249.99 a month on a one-month plan and the branded Wegovy pen at $449.99 ongoing. On tirzepatide the gap is similar, at $359.99 compounded against $549.99 for the Zepbound pen.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- sellers of the branded GLP-1 products
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- States
- 51
- From
- From $249.99/mo
- Prescription
- Required
Maximus sells both compounded preparations and the manufacturers' finished products, on plans of one, four and twelve months. The one-month plan carried $249.99 for semaglutide and $359.99 for compounded tirzepatide. The branded pens are billed monthly at $449.99 for Wegovy and $549.99 for Zepbound at the lowest dose, each $100 lower in the first month. Coverage extends to all fifty states and the District of Columbia.
Who writes the prescription, and what do they see?
Treatment is arranged online and the plan a reader buys sets the rate. The branded rows are dispensed as the manufacturer's finished product, which requires a prescription written against the approved label. The compounded rows require one as well, written for a preparation the label does not cover. What the intake asks before either is issued is not published.
Treatment is arranged online and the plan term sets the rate rather than the dose. Maximus states a flat rate across doses, so an escalation does not move the monthly figure. The longer plans cut it substantially: compounded semaglutide falls to $199.49 on four months and $150.32 on twelve. Compounded tirzepatide follows the same shape, at $298.99 and $240.66.
What happens when the dose goes up?
Maximus states a flat rate across doses, so the escalation does not move the monthly figure. What moves it is the plan length chosen at the start. A twelve-month plan is bought before the first dose step, and a one-month plan keeps that decision open at $249.99. The branded pens are priced by dose instead. Wegovy runs from $449.99 at 0.25 mg to $599.99 at 2.4 mg. Zepbound runs from $549.99 at 2.5 mg to $749.99 at 15 mg.
What the price includes
On semaglutide the branded pen costs $200 a month more than the compounded preparation on a one-month plan. On tirzepatide the gap is $190. Each pen's first month is $100 lower, and the ongoing rate is the one to budget against. Whether the longer plans apply to the branded rows is not recorded here.
What it claims, and what it cites
The branded rows are the manufacturer's own product, reviewed and approved as a finished medicine. The compounded rows are prepared by a pharmacy and are not FDA-approved. That distinction is most of what the price gap buys. Trial results for these molecules were generated with the approved products at label doses, and compounded preparations were not what was studied.
Where it holds up, and where it does not
- Strength: Branded and compounded on one plan page
- Strength: Branded pen prices published by dose
- Strength: Compounded rate stated as flat across doses
- Limitation: One-month rate is high for this category
- Limitation: Branded pens cost $190 to $200 more monthly
- Limitation: Best compounded rates need a twelve-month plan
What the evidence says about this kind of treatment
The assessment above is about Maximus. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages.
- Wrong for
- A reader shopping the compounded market on price alone, since the one-month rate here sits well above what compounded-only sellers charge.
The evidence behind what Maximus prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Maximus compares
| Seller | Who it suits | Go |
|---|---|---|
 Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | See Alloy → |
 Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | See Trimi Health → |
 Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | See Embody → |
More GLP-1 telehealth sellers reviews: Belle HealthbmiMDBodybuilding Health+CollectiveCoreAge RxDirect Meds
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Is the branded product priced near the compounded one?
- No. On a one-month plan compounded semaglutide was $249.99 against $449.99 ongoing for the Wegovy pen. Compounded tirzepatide was $359.99 against $549.99 for Zepbound.
- How much do the longer plans save?
- Compounded semaglutide drops from $249.99 to $199.49 on a four-month plan and $150.32 on twelve months. Compounded tirzepatide drops to $298.99 and $240.66 on the same terms.
- Does the price rise with the dose?
- Maximus states a flat rate across doses for its compounded plans. The branded pens are priced by dose, so an escalation there does raise the monthly figure.
- Is Maximus expensive compared with other GLP-1 telehealth sellers?
- Maximus publishes a starting figure of $249.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Maximus above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.